Navigation Links
Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Date:1/16/2008

MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Fundamental Applied Biology, Inc. (FAB) announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase IIB grant from the National Science Foundation. The $500,000 grant will be used to continue to develop FAB's cell-free protein synthesis technology towards commercialization.

During Small Business Technology Transfer (STTR) Phase I and Phase II NSF projects, FAB successfully demonstrated that certain proteins could be made in a cell-free system in a soluble form, in a controllable and efficient fashion. With the Phase IIb grant, FAB will continue to develop the technology with a market-driven, therapeutic protein as FAB's first target product.

"We are pleased to receive this grant from the NSF," said Daniel S. Gold, PhD, CEO of FAB. "The grant will allow FAB to further develop and optimize our cell-free technology to enable the production of pharmaceutical protein therapeutics with the goal of improving their biological activity."

"This grant reflects NSF's continued interest in the commercialization potential of cell-free technology. The STTR Phase I and II grants were instrumental in supporting FAB's research initiatives to develop marketable biologics as a continuation of work initiated in my laboratory at the Department of Chemical Engineering at Stanford University," noted Professor James Swartz, D.Sc.

Intact organisms which have the limitation of having to maintain their own viability can have difficulty making toxic or difficult to fold proteins. Cell-free technology was designed to overcome these limitations.

About Fundamental Applied Biology

Fundamental Applied Biology (FAB), Inc. is creating opportunities for the development of novel protein-based therapeutics and vaccines using a proprietary cell-free protein synthesis technology. Cell-free technology has the potential to overcome many of the significant limitations associated with using whole mammalian and bacterial cells for making protein-based biologics. FAB's goal is to become the leader in the field of cell-free protein synthesis by developing its own and collaborative therapies that will provide improved clinical outcomes for patients.

Contact:

Patricia Sinatra

VP, Business Development and Commercial Strategy

Fundamental Applied Biology, Inc.

(650) 329-9374

psinatra@cellfree.com

http://www.cellfree.com


'/>"/>
SOURCE Fundamental Applied Biology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndicom SpineConnect Web Platform Chosen for Applied Spines Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System
2. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
3. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
4. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
5. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
6. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
7. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
8. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
9. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
10. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
11. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Designers of primary cell wearable medical ... by 50% and extend battery life with the MAX20310 ... circuit (PMIC) from Maxim Integrated Products, Inc. (NASDAQ: ... input voltage of just 0.7V for new high-energy density ... as well as the more common Alkaline battery architecture. ...
(Date:3/29/2017)... , USA, March 29, 2017 Stryker ... that Cares by People magazine, in partnership with Great ... 50 companies on the list. This list highlights the ... have succeeded in business while also demonstrating respect, compassion ... environment.  To determine the companies on ...
(Date:3/29/2017)... March 29, 2017 /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, ... results for the year ended December 31, 2016 ... The results are being released later than the ... will include the operations and balances of Apicore ... This release and filing date meets TSX Venture ...
Breaking Medicine Technology:
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... services with or without a referral to new patients from Burnaby, BC. Patients ... or other full mouth reconstruction services, can see the esteemed team at Wall ...
(Date:3/29/2017)... ... March 29, 2017 , ... Patients interested in receiving ... from Dr. Jamie Cameron, with or without a referral. The FASTBRACES system is ... Depending on each patient’s case, treatment with the FASTBRACES system could be completed ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... it continues developing an ANSI-approved, consensus-based American National Standard for Good Manufacturing ... publish the first ANSI-approved GMP standard for dietary supplements this spring, is ...
(Date:3/29/2017)... ... 29, 2017 , ... Altima Technologies, Inc., the maker of ... center assets and audio-video devices has recently updated its Visio Stencils library with ... and download shapes and stencils from http://www.VisioStencils.com. , New devices were ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... oral braces. "The rubber bands used in conjunction with my braces always rubbed ... to design a way to prevent this problem." The O.B.S. was the result ...
Breaking Medicine News(10 mins):